The development of protein- and enzyme-based antioxidant drugs faces substantial challenges that are particularly problematic for chronic diseases like MS, including immunogenicity, high manufacturing and purification costs, limited stability, poor oral bioavailability, and unfavorable pharmacokinetic profiles that preclude long-term systemic administration ( 4.2 Pharmacodynamic and pharmacokinetic challenges of antioxidant drug development for MS Despite strong evidence implicating OS in the pathogenesis of MS, the development of antioxidant therapies has produced only limited and inconsistent clinical benefit
Conversely, the interplay of cysteine competition and glutamate secretion among various immune cells, as well as between immune cells and tumor cells, significantly impacts the survival of tumors
It is important to remember that these medications are prepared based on a specific prescription from a licensed healthcare provider
Archived from the original on 5 March 2020
Youll check in regularly with a licensed provider to monitor your progress, adjust your dose if needed, and keep things on track